These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. [Vaccination status and implementation of recommendations for vaccination with special reference to measles-mumps-rubella vaccination. 1995 program for school entrance]. Ziemer B; Blank K; Hennig R Gesundheitswesen; 1998 May; 60(5):297-300. PubMed ID: 9676011 [TBL] [Abstract][Full Text] [Related]
25. Impact of a local newspaper campaign on the uptake of the measles mumps and rubella vaccine. Mason BW; Donnelly PD J Epidemiol Community Health; 2000 Jun; 54(6):473-4. PubMed ID: 10818125 [No Abstract] [Full Text] [Related]
26. MMR vaccine is not linked to Crohn's disease or autism. Commun Dis Rep CDR Wkly; 1998 Mar; 8(13):113. PubMed ID: 9592960 [No Abstract] [Full Text] [Related]
27. Opportunistic immunisation in schools may be more effective than immunisation in hospital. Roberts RJ; Horrocks S; Kelly A; Williams S Arch Dis Child; 2000 May; 82(5):428. PubMed ID: 10836948 [No Abstract] [Full Text] [Related]
28. From the Centers for Disease Control and Prevention. Measles--United States, 1996, and the interruption of indigenous transmission. JAMA; 1997 May; 277(17):1345-6. PubMed ID: 9134928 [No Abstract] [Full Text] [Related]
29. A randomized comparative trial in order to assess the reactogenicity and immunogenicity of a new measles mumps rubella (MMR) vaccine when given as a first dose at 12-24 months of age. Gatchalian S; Cordero-Yap L; Lu-Fong M; Soriano R; Ludan A; Chitour K; Bock HL Southeast Asian J Trop Med Public Health; 1999 Sep; 30(3):511-7. PubMed ID: 10774661 [TBL] [Abstract][Full Text] [Related]
30. Efficacy of two dose measles vaccination in a community setting. Phadke MA; Bhargava I; Dhaigude P; Bagade A; Biniwale MA; Kurlekar SU Indian Pediatr; 1998 Aug; 35(8):723-5. PubMed ID: 10216565 [TBL] [Abstract][Full Text] [Related]
31. Measles, mumps and rubella immunisation in Fife--first experience. Carter H; Walker D Midwife Health Visit Community Nurse; 1988 Dec; 24(12):504-8. PubMed ID: 3231144 [No Abstract] [Full Text] [Related]
33. MMR immunisation coverage in Christchurch. Christchurch Immunisation Coordination Committee. Ford RP; Bell DW; Slade B; McCormack SP N Z Med J; 1998 Aug; 111(1071):301. PubMed ID: 9760956 [TBL] [Abstract][Full Text] [Related]
34. Clinical and serologic evaluation of measles, mumps, and rubella (HPV-77:DE-5 and RA 27/3) virus vaccines, singly and in combination. Lerman SJ; Bollinger M; Brunken JM Pediatrics; 1981 Jul; 68(1):18-22. PubMed ID: 7017582 [TBL] [Abstract][Full Text] [Related]
35. Measles--United States, 1996, and the interruption of indigenous transmission. Centers for Disease Control and Prevention (CDC) MMWR Morb Mortal Wkly Rep; 1997 Mar; 46(11):242-6. PubMed ID: 9082179 [TBL] [Abstract][Full Text] [Related]
36. [A seroconversion study of the measles component of the MMR vaccine in adolescents of the town of Sabrosa]. Gonçalves G; Tavares F; de Andrade HR Acta Med Port; 1998 Dec; 11(12):1079-84. PubMed ID: 10192981 [TBL] [Abstract][Full Text] [Related]
37. Evidence to support current policy on MMR vaccination sent to doctors in the United Kingdom. Commun Dis Rep CDR Wkly; 1998 Apr; 8(14):123, 126. PubMed ID: 9592964 [No Abstract] [Full Text] [Related]
38. Approaching the NHMRC goal for second-dose measles-mumps-rubella vaccine uptake. Donelly JK; Kelly HA Med J Aust; 1995 Jun; 162(11):613. PubMed ID: 7791653 [No Abstract] [Full Text] [Related]